Audit: QRS - N-Acetylcysteine for Health & Longevity

Audit conducted on 22/09/2026 18:57 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	94
Passed	84
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every cell traces to ER text: protocol values to Therapeutic Protocol, time values to Practical Considerations, benefit/risk items to the ER tier headings, biomarker rows to the ER monitoring table.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Speculative tiers stay speculative; marker_10 carries the ER’s “No established target range” wording verbatim.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Absolute contraindications stay in the Contraindications gate; “Monitor”/”Caution” ER bullets stay in Key Interactions.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Gates draw only from Key Interactions & Contraindications; benefits/risks only from their own ER sections; no modifying factors were promoted.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT IDs, author names, or brands appear anywhere in the sheet; “World Anti-Doping Agency” is present in the ER for the same fact.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind are introduced.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Lede mirrors the ER Conclusion register (“thins the blood and damps the signals that drive training adaptation”).
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Tiered benefits and risks presented side by side without alarm or promotion.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Protocol and monitoring cells are declarative schedules, not orders.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	Cadence line reads “Baseline before starting… Dosing pauses 48 hours before every draw”, stating practice rather than prescribing it.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No “recommended”, “advised”, or “should” constructions in any variable.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronoun appears in any data-qrs-var span.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	COPD rendered as “obstructed airway disease”; glutathione glossed in the lede; remaining terms are the ER’s own and suit the audience.
2.8	Information is presented in a concise and very compact manner	🟢	Benefit and risk tiers are semicolon-separated ER headings; gate items are single lines.
2.9	It DOES NOT address the reader directly	🟢	Confirmed — no direct address in any populated span.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Training-adaptation, supplement-stacking, and biomarker framing target exactly this reader.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	10-marker panel, 48-hour dosing pause before draws, and divided daily dosing assume a willing reader.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No general-population simplification; optimal functional ranges are used rather than conventional lab flags.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The lede closes on the two audience-specific costs (bleeding, blunted training adaptation), as the ER Conclusion does.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“anti-aging” appears nowhere; title and header use “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	Route stated as “oral supplement” and “divided doses”; no “pill”, “shot”, or “taken by mouth”.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: • Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” • Gate headings: “Contraindications”, “Key Interactions” • Tier labels: “High”, “Medium”, “Low”, “Speculative” • Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	Diff against [qrs_template] shows every fixed heading, gate head, tier label, and column header byte-identical.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 template variable names present; the repeatable marker_#_* and qualitative_item_# spans are expanded to 10 and 6 instances.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Structural diff against the template shows changes confined to metadata and populated variable spans; CSS, website= spans, and footer are untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section that feeds the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Standard maintenance dose”, “Best time of day”, “Combined glycine protocol” match the ER Therapeutic Protocol bold labels verbatim; gate items carry the ER bullet labels verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Protocol and gate labels are ER labels; time-to-effect labels track the ER’s own phrases (“Glutathione repletion”, “exercise-recovery”, “mood and aging-hallmark”), which the ER states without bold labels.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji in the file; the ER’s “⚠️ Conflicted” marker on the depression benefit was correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed to the template’s budget: four single-line benefit/risk tiers, seven items per gate, three protocol and three time cells, ten table rows. No section was extended.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after the doctype at line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13; the title text sits on line 2.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Wholly inside the HTML comment; no duplicate on the page.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:02" is quoted, correctly, because it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	er_filename: n_acetylcysteine_2026-0815-0247_Opus_ER.md (line 4) matches the ER frontmatter filename.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.9.22 matches the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	qrs_creation_date: 2026-0922-1840.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no context-window or other qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	qrs_filename: n_acetylcysteine_2026-0815-0247_Opus_QRS.html matches the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	“N-Acetylcysteine for Health & Longevity - Quick Reference Sheet” (line 22), matching the ER canonical_topic with the ampersand encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	“N-Acetylcysteine for Health & Longevity” (line 417).
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	“09/22/2026” (line 421) from qrs_creation_date: 2026-0922-1840.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	“Opus 5” (line 425).
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header holds only title and the template subline; the ER’s “Also known as” list was not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence	🟢	Opens “an inexpensive oral supplement, a modified amino acid that supplies raw material for glutathione, the body’s main internal antioxidant” — kind and purpose precede the evidence verdict.
7.2	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Compresses all four movements of the ER Conclusion: what it is, strongest evidence, weak aging claims, and the two audience-relevant costs.
7.3	[at_a_glance] is no longer than 70 words	🟢	67 words.
7.4	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	“inexpensive” (Motivation), the three strong indications, the one-laboratory aging caveat, and the bleeding/adaptation costs each map to a distinct ER passage.
7.5	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; COPD rendered as “long-standing airway disease”, glutathione glossed inline.
7.6	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years, or sample sizes.
7.7	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numeric results of any kind.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All seven items trace to that section’s absolute contraindications and its “Populations who should avoid” list.
8.2	[stop_items] represent the Contraindications from the ER	🟢	Both ER absolute contraindications (nitrates; prednisone plus azathioprine in pulmonary fibrosis) plus all five avoid-populations are present.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Seven discrete <li> elements (lines 542–548).
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	ER rationales (“on precautionary grounds given the preclinical tumor-promotion data”, “since lactation safety has not been assessed”) stripped; no trailing dash clauses.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Retains the nitrate drug list, “within 14 days”, “below 100 ×10⁹/L”, “past 5 years”, “Child-Pugh Class C”, “stage 4–5”, and “below 30 mL/min/1.73 m²”.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER identifies several, and the section is correspondingly populated.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All seven items map one-to-one to ER bullets in that section.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All seven non-contraindication ER bullets are present; nitrates and the immunosuppressive combination correctly appear only in the Contraindications gate.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Seven discrete <li> elements (lines 556–562).
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Mechanisms and mitigations (“Mitigation is separating oral doses by at least two hours”, “so oral use is permitted for competing athletes”) stripped; no trailing dash clauses.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Each drug/supplement example list is carried, and the anti-doping threshold (“above 100 mL per 12 hours”) is preserved.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER identifies several, and the section is correspondingly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells derive from the ER Therapeutic Protocol bullets.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose, timing, and the glycine-combined regimen — the three decisions the ER’s protocol bullets turn on.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies more than three; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	“600–1,800 mg daily”, “Between meals”, “~100 mg/kg of each daily” with ER-derived subs; no placeholders remain.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Matches the three the ER names in Practical Considerations: glutathione repletion, exercise recovery, mood and aging-hallmark change.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Ordered High (glutathione restoration) → Medium (exercise recovery) → Medium/Speculative (mood and aging markers).
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three; all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	“~2 weeks”, “Within days”, “8–16 weeks” with ER-derived subs.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All twelve listed benefits are the ER’s own benefit headings, tier by tier.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated (lines 521–532).
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	ER magnitude lines (SMD, odds ratios, confidence intervals) and all citations are absent.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses in any benefits span; the ER’s “⚠️ Conflicted” marker on the depression benefit is dropped.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER benefit tiers contain items.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All nine listed risks are the ER’s own risk headings, tier by tier.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated (lines 574–585).
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	ER magnitude lines (odds ratios, prothrombin-time percentages, the 14% headache rate) and citations are absent.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses in any risks span.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER risk tiers contain items.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Rows and cadence both come from the ER Monitoring Protocol & Defining Success section.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All ten rows of the ER biomarker table are carried over with their optimal ranges and “Why Measure It?” text intact.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Baseline, 12 weeks, 6–12 months, the 6-month trace-mineral/TSH step above 1,200 mg daily, and the 48-hour pre-draw pause all match the ER.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All six items come from the ER’s qualitative-markers list in that section.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER qualitative markers are present and in ER order.

Issues 22/09/2026 18:57

Pass rate 100.00%. No issues found.

Issues 22/09/2026 18:49

1. 1.3 / 9.5 — Anti-doping qualifier dropped: Line 562 states intravenous infusions above 100 mL per 12 hours are “prohibited under the 2026 World Anti-Doping Agency list”, dropping the ER’s qualifier “without a clear medical indication” (ER line 345) and so stating a broader prohibition than the source.
2. 12.3 — “conflicted” qualifier in Benefits: Line 525 reads “reduction in depressive symptoms as an add-on, conflicted”; the trailing evidence-strength qualifier is redundant with the Medium tier and leaves a dangling fragment.

Fixes 22/09/2026 18:49

1. 1.3 / 9.5 — Anti-doping qualifier restored: The Key Interactions anti-doping item now reads “intravenous infusions above 100 mL per 12 hours without a clear medical indication prohibited under the 2026 World Anti-Doping Agency list”, restoring the ER’s qualifier so the prohibition is no longer stated unconditionally.
2. 12.3 — “conflicted” qualifier removed: The Medium benefits item was changed from “reduction in depressive symptoms as an add-on, conflicted” to “reduction in depressive symptoms as an add-on”, dropping the redundant evidence-strength qualifier already encoded by the tier.

Issues 22/09/2026 18:46

1. 2.15 — Colloquial term in lede: [at_a_glance] (line 433) says “preventing liver injury after painkiller overdose”; “painkiller” is consumer-grade language where the QRS’s own voice uses formal terminology elsewhere (“acetaminophen overdose”, line 522).

Fixes 22/09/2026 18:46

1. 2.15 — Colloquial term in lede: Replaced “painkiller overdose” with “acetaminophen overdose” in [at_a_glance] (line 433), aligning the lede with the formal terminology used elsewhere in the QRS. Word count remains within the 70-word budget.